cyrilzakka/clinical-trials huggingface dataset:
Ambient Air Pollution, Preeclampsia, and Preterm Delivery

An epidemiologic study of pregnant women in western Washington to measure the relationships between exposure to air pollutants and risks of preeclampsia and preterm delivery.

We will design models that use local traffic, weather, and population characteristics to predict monthly ambient concentrations of fine particulate matter (PM2.5) and carbon monoxide (CO). These models will be used to estimate study participants' PM2.5 and CO exposures during and before pregnancy. We will test whether these air pollutant exposures are associated with subsequent risk of preeclampsia and preterm delivery. Additionally, we will test biological markers of maternal lipid peroxidation (thiobarbituric acid reactive substances) and inflammation (high sensitivity C-reactive protein) in maternal blood samples drawn during early pregnancy. We will also examine carboxyhemoglobin measured in early-pregnancy maternal blood samples as a marker of CO exposure.

Eligibility Criteria:
Inclusion Criteria:

* English speaking
* enrolled in parent study
* pregnant at \<20 weeks gestation and attending prenatal care clinics affiliated with Swedish Medical Center and Tacoma General Hospital

Exclusion Criteria:

-
Effect of Infraorbital and Infratrochlear Nerve Block on Emergence Agitation in Patients Undergoing Septorhinoplasty

The purpose of this study is to determine whether bilateral infraorbital and infratrochlear nerve block in patients undergoing septorhinoplasty are effective in preventing emergence agitation.

Emergence agitation is a postanesthetic phenomenon characterized as confusion, disorientation and violent behavior. Although its etiology is not well understood, risk factors associated with the condition include pain and ENT (ear, nose and throat) surgery. Bilateral infraorbital and infratrochlear nerve block in patients undergoing septorhinoplasty is effective in treating postoperative pain. The investigators have designed this study to evaluate the effect of infraorbital and infratrochlear nerve block on emergence agitation in patients undergoing septorhinoplasty.

Eligibility Criteria:
Inclusion Criteria:

* Septorhinoplasty
* American Society of Anesthesiologists (ASA) classification I-II
* Written informed consent

Exclusion Criteria:

* ASA classification greater than III
* Allergy to ropivacaine
* Incapability to give consent
* Chronic pain
* Coagulopathy
Optimization of Drug Treatment in Hospitalized Elderly (OMAGE)

A randomized trial has been designed to determine if this complex intervention can significantly decrease the risk of unplanned readmissions in this very elderly population, compared with usual care.

Drug treatment in elderly is not yet optimal. 20 to 30% of admissions of elderly aged over 80 are related to drug problems, most of them being preventable. To decrease drug related hospitalizations need iatrogenic prevention, compliance improvement, and underuse decrease. A multifaceted intervention has been designed, included three dimensions : 1/ drug optimization 2/ patient and/or caregiver education and 3/ better coordination with home health professionals before discharge.

A randomized trial has been designed to determine if this complex intervention can significantly decrease the risk of unplanned readmissions in this very elderly population, compared with usual care.

Eligibility Criteria:
Inclusion Criteria:

* Patients hospitalized as a matter of urgency in unity(unit) of geriatrics acute
* Patients of more than 70 years old
* Hospitalization in the Unity(Unit) of Geriatrics foreseen(planned) superior acute in 5 days
* enlightened assent writing and signed
* preliminary medical examination

Exclusion Criteria:

* Patients in scheduled(programmed) hospitalization
* Patient in palliative care
* Patient whose vital forecast is engaged(opened) in 3 months
* Patient already include during a previous hospitalization Patient already included in a study concerning the therapeutic care
* Followed medical impossible (refusal of care, absence of alive regular, patient doctor abroad)
* not membership to a regime of Social Security or CMU
* Patient not speaking French
Impact of Acute ITTP Therapies on Long Term Neurologic and Cognitive Outcomes in ITTP Survivors

1. We expect to find that the silent cerebral infarct (SCI) rate is two fold higher in patients treated without caplacizumab. We also expect to find that the rate of mild and major cognitive impairment in patients treated with caplacizumab within 3 days of starting plasma exchange will be lower than patients treated without caplacizumab.
2. We expect that the differences in cognitive impairment in cases (caplacizumab) versus controls (no caplacizumab) will persist on serial evaluation 1 year later. We also expect that there will be differences in these groups even after adjusting for time since episode and severity of presentation.
3. We expect to find that SCI and cognitive impairment is associated with worse scores on the health related quality of life instrument (SF-36)
4. Based on studies in non-TTP populations, we expect to find that the rate of incident stroke over the period of follow up is at least 2 fold higher in patients that have SCI compared with patients who do not have SCI


Eligibility Criteria:
Inclusion Criteria:

1. Age \>= 18 years
2. Confirmed iTTP based on ADAMS13 activity \< 10 % (or 10-20% with positive inhibitor or antibody) during an acute iTTP episode
3. Only 1 episode of iTTP that was treated with plasma exchange and caplacizumab started within 3 days of diagnosis (or if more than 1 episode, then all episodes treated with plasma exchange and caplacizumab started within 3 days of diagnosis)

Exclusion Criteria:

1. Any contraindication for MRI (metallic implants, shrapnel, MRI incompatible stents, etc)
2. Unable to speak, read or understand instructions in English (for NIH ToolBox)
3. Combination of iTTP episodes treated without caplacizumab or with caplacizumab.
4. Caplacizumab started at \>= 4 days from diagnosis or for refractory iTTP
Learning Skills Together Pilot Study

The Learning Skills Together (LST) program is a synchronous web-based educational intervention developed to address the essential need for training to equip family caregivers to someone with mid-stage Alzheimer's disease to confidently provide complex care tasks.The purpose of this pilot study is to evaluate the feasibility of delivering LST, the program's acceptability to caregivers, and likelihood of effecting caregivers self-efficacy and mastery.


Eligibility Criteria:
Inclusion Criteria:

* Family member (including families of choice) to an individual living with Alzheimer's disease who has received a diagnosis from a physician
* Ages 18 and old
* Provides assistance with at least two instrumental activities of daily living or one activity of daily living
* Care recipient is described as being within mid-stage Alzheimer's Disease
* There are no plans to place the care recipient in a skilled nursing facility within the next 3 months

Exclusion Criteria:

* The caregiver is paid to provide care
* The caregiver does not have reliable access to a computer and internet
* The caregiver is unable to read and speak English
Autoimmune Thyroid Disease Genetic Study

The hypothesis of this project is that specific genes can be identified that contribute to genetic susceptibility to autoimmune thyroid disease (AITD) in different populations. The specific aim of this project is carry out one or more genomewide association studies (GWAS) to map and ultimately identify genes that confer susceptibility to AITD. AITD consists principally of Hashimoto's Thyroiditis (HT) and Graves' Disease (GD), characterized clinically generally by hypothyroidism and hyperthyroidism, respectively. Both HT and GD are autoimmune diseases characterized by infiltration of the thyroid by T and B cells that are reactive with thyroid antigens and by the production of thyroid autoantibodies (TAB). While there is some evidence that there may be genes specific to either GD or HT, other genes appear to be common to both, and some genes may furthermore be in common to susceptibility to other autoimmune diseases. Genes known to play a role in AITD include HLA, CTLA4, thyroglobulin (TG), THSR, and CD40, PTPN2, and PTPN22, several of which are also involved in susceptibility to other autoimmune diseases. All of these genes interact in a complex manner that has yet to be understood. Furthermore, it seems clear that relatively few of the genes involved in susceptibility to AITD have thus far been discovered.


Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of abnormal thyroid function (hypo or hyperthyroidism) due to autoimmune thyroid disease

Exclusion Criteria:

* Lack of documentation of abnormal thyroid function or clear evidence of autoimmune etiology
Using Traditional Acupuncture in the Management of Cancer Treatment Related Lymphoedema

RATIONALE: Acupuncture and moxibustion may improve well-being and quality of life in patients with lymphedema caused by breast cancer or head, neck, and throat cancer.

PURPOSE: This clinical trial is studying how well acupuncture given together with moxibustion works in improving well-being and quality of life in patients with breast cancer or head, neck, and throat cancer who are undergoing standard treatment for lymphedema.

OBJECTIVES:

* To test the acupuncture and moxibustion treatment strategies to obtain a first measure of response for the approach(es) used in patients with breast cancer or head, neck, and throat cancer undergoing standard treatment for secondary lymphedema.
* To assess whether this treatment is an acceptable intervention to cancer patients with secondary lymphedema and to their health care professionals.
* To disseminate the data to begin to build the evidence base for using this treatment in the management of lymphedema.

OUTLINE: Patients undergo acupuncture and moxibustion therapy once weekly for 7 treatment (Series 1). After completion of therapy, patients may choose to continue treatment for an additional 6 treatments (Series 2).

Patients complete a set of 4 questionnaires (i.e., sociodemographic, Short-Form-36, Positive and Negative Affect Scale (PANAS), and Measure Yourself Medical Outcome Profile (MYMOP)) at the first treatment and then periodically during study. Patients also complete a series of follow-up questionnaires designed to elicit feedback about their acupuncture experience.

After completion of study treatment, patients are followed at 1 and 3 months.

Eligibility Criteria:
INCLUSION CRITERIA:

* male or female patients with either breast or head and neck cancer
* diagnosis of mild to moderate uncomplicated lymphoedema
* age 18 or over
* under the care of the lymphoedema service for at leas:
* two months (head and neck cancer patients)
* three months (breast cancer patients)
* no active cancer disease
* at least 3 months since prior active cancer treatment (surgery, radiotherapy, chemotherapy, intravenous treatment)
* more than 6 months since prior acupuncture treatment
* concurrent adjuvant hormonal therapy allowed
* concurrent anti-depressant medication allowed provided there has been no change in prescription or dosing within the past 3 months and patient intends to remain on the medication for the duration of study treatment and follow-up
* Able to understand and communicate in English
* Able to travel to the Lynda Jackson Macmillan Centre for treatment
* Able to attend treatment once weekly for at least 7 consecutive weeks
* Able to complete outcome measures

EXCLUSION CRITERIA:

* bilateral breast cancer
* advanced cancer disease
A Study on Radiation Therapy Guided by the Reflectance Confocal Microscopy (RCM)/Optical Coherence Tomography (OCT) Device in People With Basal Cell Carcinoma

The purpose of this study is to find out if radiation therapy (RT) guided by the new reflectance confocal microscopy (RCM)/optical coherence tomography (OCT) device is an effective treatment for basal cell carcinoma (BCC). The researchers will also look at the side effects from RT guided by the RCM/OCT device. In addition, will determine the quality of life before and after treatment by having the participant fill out questionnaires.


Eligibility Criteria:
Inclusion Criteria:

* Biopsy proven basal cell carcinoma

  °Up to 3 tumors per patient can be treated per protocol synchronously or metachronously
* Clinical stage T1 or T2 by Union International to Control Cancer 8th edition system

  * ≤40 mm in maximum dimension
  * no deep invasion (beyond subcutaneous fat or \>6 mm from granular later of dermis to deepest point of carcinoma)
  * no perineural invasion of nerves ≥0.1 mm diameter or deeper than dermis
  * no intraneural invasion
  * no bone erosion, invasion or foraminal transgression NOTE: For the purposes of protocol inclusion, if any of the features mentioned above is not included in the pathology report they will considered absent.
* ≥18 years old
* Amenable to RCM/OCT and radiation therapy in opinion of investigator

  * Some anatomic locations may preclude imaging by RCM/OCT may not be amenable to RCM/OCT imaging
  * Some medical comorbidities may preclude the delivery of radiation therapy (conditions rendering patients hypersensitive to ionizing radiation, or unable to undergo treatment)
* Able and willing to complete the Skindex 16 and Skin Cancer Index (must be able to understand English or Spanish)

Exclusion Criteria:

* Medical contraindication to radiation therapy in the opinion of the investigator
* Prior cancer radiotherapy which precludes the ability to safely deliver radiation therapy in the opinion of the investigator
* High likelihood of protocol non-compliance in the opinion of the investigator °Patients who demonstrate unwillingness to undergo protocol-defined treatment or follow-up procedures will be ineligible to participate
Abbott Sensor Based Glucose Monitoring System Paediatric Study

To evaluate the point accuracy of the Abbott Sensor Based Glucose Monitoring System when used at home by children with diabetes.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 4 years, ≤17 years
* Each participant has an identified Caregiver of ≥18 years
* Type 1 or type 2 diabetes using insulin administered by injections or continuous subcutaneous insulin infusion (CSII)
* Currently testing blood glucose, on average at least 2 times per day
* In the investigator's opinion, technically capable of using device (participant and/or caregiver).

Exclusion Criteria:

* Concomitant disease or condition that may compromise patient safety including and not limited to; cystic fibrosis, severe mental illness, known or suspected eating disorder or any uncontrolled long term medical condition
* Currently prescribed oral steroid therapy for any acute or chronic condition
* Currently receiving dialysis treatment or planning to receive dialysis during the study
* Female participant known to be pregnant
* Participating in another study of a glucose monitoring device or drug that could affect glucose measurements or management
* Currently using a continuous glucose monitoring (CGM) device
* Known (or suspected) allergy to medical grade adhesives
* In the investigator's opinion the participant or caregiver is unsuitable to participate due to any other cause/reason (both patient and caregiver considered)
Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing

The aims of this study are to compare the effect and durability of two stress and symptom management programs tailored for patients with neurofibromatosis on quality of life and psychosocial functioning.

The aims of this study are to compare the effect of two stress and symptom management programs tailored for patients with neurofibromatosis on quality of life and psychosocial functioning. We will also examine the degree to which treatment-dependent improvements in quality of life are mediated by improvements in depression, anxiety, distress, mindfulness, gratitude, social support, empathy, optimism, coping, pain intensity and pain interference.

Eligibility Criteria:
Inclusion Criteria:

* Has a diagnosis of NF1, NF2, or Schwannomatosis
* 18 years of age or older
* Is capable of completing and fully understanding the informed consent process, study procedures, and study assessments in English
* At least 6th grade self-reported reading level
* Self-reported difficulties coping with stress and NF-symptoms
* Score of 6 or higher on Perceived Stress Scale 4-Item (PSS-4)

Exclusion Criteria:

* Has major medical comorbidity not NF related expected to worsen in the next 12 months
* Recent (within past 3 months) change in antidepressant medication
* Recent (within past 3 months) participation in cognitive behavioral therapy or relaxation therapy
* Has significant mental health diagnosis requiring immediate treatment (e.g., bipolar disorder, psychotic disorder, active substance use dependence)
* Unable or unwilling to complete assessments electronically via REDCap
* Unable or unwilling to participate in group videoconferencing sessions
Bioactive Lipids & PBMC

The investigators aim at harvesting PBMC from healthy donors to study the effect of the lipids mediators of interest. After isolation from the blood, PBMC will be activated as largely reported in the literature in the presence or absence of the tested lipids. The effect will be assessed by quantifying the expression of inflammatory markers. The expression of the receptors and enzymes potentially regulating the effects of the studied lipids will also be assessed.

Data from the scientific literature support the hypothesis that bioactive lipids play an important role in inflammatory disorders. The levels of these bioactive lipids are altered in several pathophysiological conditions with an inflammatory component. The investigators and others have demonstrated that bioactive lipids affect the inflammatory tone in vivo in murine models as well as in in vitro models. However, confirming the translational value of these data is not easy in clinical studies. PBMC-based experiments are a powerful tool for us to validate our previous observations and will offer translational added value supporting further clinical investigations.

Thus, here the investigators aim at harvesting PBMC from healthy donors and use them to study the effect of the lipid mediators of interest (i.e. those showing interesting properties in our preclinical models). Blood will be collected from healthy volunteers, and PMBC isolated based on their density. After isolation from the blood, PBMC will be activated as largely reported in the literature (e.g. using phytohemagglutinin or lipopolysaccharides) in the presence or absence of the tested lipids. The effect will be assessed by quantifying the expression of inflammatory markers (by RT-qPCR and/or ELISA). The expression of the receptors and enzymes potentially regulating the effects of the studied lipids will be also assessed (by RT-qPCR).

Eligibility Criteria:
Inclusion Criteria:

* Volunteers must be able to give informed consent to be included in the study.
* no chronic inflammatory disease
* no acute inflammation

Exclusion Criteria:

* Men and women aged less than 18 years
* Pregnant women
* Prior diagnosis of a chronic inflammatory disease (for instance IBD, COPD, lupus, MS, etc. This is not an exhaustive list).
* Recent (\<21 days) episode of acute inflammation or immune-altering event (e.g. cold, flu, vaccine, ...).
* Chronic or recent use of drugs interfering with the immune / inflammatory response. Examples include (and are not limited to) NSAIDs, corticosteroids, aspirin, mABs, etc.
* Unable to give informed consent
Cough Assist in Bronchiolitis

RSV bronchiolitis in children is still associated with significant morbidity and mortality. RSV infection results in increased mucus production, edema and inflammation at the lower airways and impaired mucociliary clearance. Infants and children under the age of 1 year are particularly vulnerable to complications such as atelectasis and secondary bacterial infection. These children often need non-invasive or invasive ventilation. Atelectasis is common in these children because of smaller airways and decreased cough strength. There is still much uncertainty about the treatment of RSV. Treatment consists primarily of supportive therapy such as tube feeding and additional respiratory support if necessary. There is also limited evidence about the use of nebulizers with beta-agonists and/or hypertonic saline.

The cough assist is a mechanical in- and exsufflator used primarily in patients with neuromuscular diseases to augment cough capacity. In these patients, it was demonstrated that the use of assisted cough resulted in a significant decrease in the number of respiratory infections. Moreover, there is evidence that when used in the case of an acute respiratory deterioration such a massive atelectasis, the atelectasis can be corrected and intubation can be avoided. The aim of this study is to investigate if the use of the CoughAssist device in children with RSV bronchiolitis is associated with a better respiratory outcome.


Eligibility Criteria:
Inclusion Criteria:

* Children between 3 and 18 months admitted to our hospital with a clinical diagnosis of bronchiolitis in the RSV season or with a positive nasopharyngeal aspirate for RSV.

Exclusion Criteria:

* Children with congenital cardiac disease.
* Children with cystic fibrosis.
* Children with reactive airways disease.
* Children with neurological impairment including cerebral palsy.
* Children with neuromuscular disease.
* Children with upper GI surgery.
* Children with emphysema.
* Children with a known susceptibility to pneumothorax or with a pneumothorax in the past.
Pre-operative Radiograph of Deep Carious Lesions as a Predictive Tool for Pulpal Exposure

Preserving pulpal vitality is a major challenge when excavating deep caries lesions without severe symptomatology. Pulpal exposure alters success of the treatment (dropping from 93% for indirect pulp treatment with selective excavation to 11% for direct pulpotomy) and thus prognosis of dental organ and cost-effectiveness of the treatment. The preoperative x-ray is a complementary examination which allows to estimate the depth of the carious lesion. In clinical practice, it is currently difficult to accurately measure this depth on preoperative radiographs. This lack of precision leads to a decrease in the effective capacity of the operator to predict the risk of pulpal exposure. Their interpretation is considered imprecise and is not used as a diagnostic element.

The aim of this study was to determine if the use of pre-operative retroalveolar radiographs can help to predict pulpal exposure risk.


Eligibility Criteria:
Inclusion Criteria:

-pre-operative radiographs of deep carious lesions treated with DECAT protocole, unless they were out of the study.

Exclusion Criteria:

* Impossibility to assess carious lesion on radiograph, and amalgam restorations that impairs correct examination of carious lesion
* Radiographs of poor quality and screen captures